Advertisement
Document › Details
Sartorius AG. (9/30/22). "Press Release: Sartorius Completes Acquisition of Albumedix". Göttingen.
Organisation | Sartorius Stedim Biotech S.A. (SSB) | |
Group | Sartorius (Group) | |
Organisation 2 | Albumedix Ltd. | |
Group | Sartorius (Group) | |
Product | bioreactor, disposable | |
Index term | Albumedix–Sartorius: investment, 202208–202209 acquisition £415m 100% of Albumedix by Sartorius Stedim Biotech | |
The life science group Sartorius, through its French listed subgroup Sartorius Stedim Biotech, has successfully closed the acquisition of Albumedix Ltd. as of September 30, 2022. Albumedix is a leader in the field of recombinant albumin-based solutions and based in Nottingham, UK.
This press release contains forward-looking statements about the future development of the Sartorius Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius assumes no liability for updating such statements in light of new information or future events. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version.
A profile of Sartorius
The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2021, the company earned sales revenue of some 3.45 billion euros. At the end of 2021, nearly 14,000 people were employed at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.
Contact
Philipp Grontzki
Head of External Communications
+49 (0)551.308.5581
philipp.grontzki@sartorius.com
Follow Sartorius on Twitter @Sartorius_Group and on LinkedIn.
Record changed: 2024-01-06 |
Advertisement
More documents for Sartorius (Group)
- [1] Sartorius AG. (8/3/23). "Press Release: Florian Funck Appointed CFO of Sartorius. New CFO to Take Over as of April 2024". Göttingen....
- [2] Waters Corporation. (6/5/23). "Press Release: Waters and Sartorius Expand Collaboration to Deliver Comprehensive Bioanalytics for Downstream Biomanufacturing". Milford, MA & Göttingen....
- [3] Sartorius. (3/31/23). "Press Release: Sartorius to Acquire Polyplus. France-based Polyplus Is a Provider of Innovative Upstream Technologies for Cell and Gene Therapies". Göttingen....
- [4] Polyplus-transfection S.A.. (12/17/22). "Press Release: Polyplus Acquires Xpress Biologics to Expand Plasmid DNA Offer". Strasbourg....
- [5] Sartorius AG. (11/11/22). "Press Release: Sartorius Successfully Places Schuldschein Loans with a Volume of 650 Million Euros". Göttingen....
- [6] Sartorius AG. (8/8/22). "Press Release: Sartorius to Acquire Albumedix, Strengthening Its Portfolio of Innovative Advanced Therapy Solutions". Göttingen....
- [7] Sartorius Stedim Biotech S.A.. (7/21/22). "Press Release: Half-year Results 2022 of Sartorius Stedim Biotech. Sales Revenue up 22.1 Percent in Constant Currencies, Underlying EBITDA Margin 35.2 Percent ". Aubagne....
- [8] Sartorius AG. (7/21/22). "Press Release: Sartorius Remains on Growth Track. Figures for the First Half of 2022 – Sales Revenue up 20.9 Percent in Constant Currencies, Underlying EBITDA up 25.6 Percent, Underlying EBITDA Margin 33.9 Percent". Göttingen...
- [9] mk2 Biotechnologies GmbH. (6/28/22). "Press Release: mk2 Biotechnologies and Sartorius Stedim Biotech Join Forces to Develop a Biologics Production Platform"....
- [10] Polyplus-transfection S.A.. (3/9/22). "Press Release: Polyplus-transfection Acquires Biowire to further Expand into Asia-Pacific Gene and Cell Therapy Markets". Strasbourg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top